March 11, 2021, Vancouver, Canada – iCo Therapeutics Inc. (TSXV: ICO) (OTCQB: ICOTF) (“iCo” or the
“Company”), announces that between February 1, 2021 and March 12, 2021, 20,280,000 warrants of the
Company were exercised for common shares in the capital of the Company resulting in proceeds to the
Company of $1,301,200.00.
William Jarosz, the Chief Executive Officer of iCo commented, “We deeply appreciate this show of support
from our warrant holders. These funds will help us more rapidly advance strategic opportunities we’ve been
pursuing.”
About iCo Therapeutics
iCo Therapeutics identifies existing development stage assets for use in underserved ocular and infectious
diseases. Such assets may exhibit utility in non-ophthalmic conditions outside the Company’s core focus
areas and if so, the Company will seek to capture further value via partnerships. iCo shares trade on the
TSX Venture Exchange under the symbol “ICO” and on the OTCQB under the symbol “ICOTF”.
For more information, visit the Company website at: icotherapeutics.cdmail.biz.
No regulatory authority has approved or disapproved the content of this press release. Neither the TSX
Venture Exchange nor its Regulatory Services Provider (as that term is defined in the policies of the TSX
Venture Exchange) accepts responsibility for the adequacy or accuracy of this press release.
Forward-Looking Statements
Certain statements included in this press release may be considered “forward-looking information” within
the meaning of applicable securities laws. Forward-looking information can be identified by words such as:
“anticipate”, “intend”, “plan”, “goal”, “seek,” “believe,” “project,” “estimate,” “expect,” “strategy,” “future,”
“likely,” “may,” “should,” “will” and similar references to future periods. Such statements involve known and
unknown risks, uncertainties and other factors that may cause actual results, performance or achievements
to be materially different from those implied by such statements, and therefore these statements should not
be read as guarantees of future performance or results. Forward-looking statements in this press release
include statements pertaining to the use of funds received from the exercise of warrants. All forward-looking
statements are based on iCo’s current beliefs as well as assumptions made by and information currently
available to iCo and relate to, among other things, anticipated financial performance, business prospects,
strategies, regulatory developments, market acceptance and future commitments. Readers are cautioned
not to place undue reliance on these forward-looking statements, which are based only on information
currently available to iCo and speak only as of the date of this press release. Due to risks and uncertainties,
including the risks and uncertainties identified by iCo in its public securities filings and on its website, actual
events may differ materially from current expectations. iCo disclaims any intention or obligation to update
or revise any forward-looking statements, whether as a result of new information, future events or otherwise,
except as required by law.
Contact:
Investor Relations
iCo Therapeutics Inc.
1-604 800 9860
51248194.1